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CTLA-4 Is a Direct Target of Wnt/b-Catenin Signaling
and Is Expressed in Human Melanoma Tumors
Kavita V. Shah1, Andy J. Chien2, Cassian Yee2,3 and Randall T. Moon1,4
Our goal was to identify genes regulated by Wnt/b-catenin signaling in melanoma cells, as this pathway has
been implicated in melanocyte development and in melanoma biology. We therefore undertook transcriptional
profiling of UACC 1273 human melanoma cells following treatment with recombinant Wnt-3a and found that
cytotoxic T-lymphocyte antigen-4 (CTLA-4) was the most highly induced gene. We observed CTLA-4 expression
in human epidermal melanocytes and in patient-derived primary melanoma tumors and found that Wnt/
b-catenin signaling elevates CTLA-4 expression in two cultured melanoma cell lines. CTLA-4 is likely a direct
target of Wnt/b-catenin signaling, as the b-catenin responsiveness of a 1.7 kb region of the CTLA-4 promoter
requires a T-cell factor-1/lymphoid enhancing factor-1 consensus site present at 114 to 119 bp from the
transcriptional start site. These findings are the initial demonstration that CTLA-4 is a direct target of Wnt/
b-catenin signaling and the first report of its expression in primary melanoma tumors and melanocytes. Given
the described role of CTLA-4 in inhibiting the immune response, these findings may shed light on the role of
Wnt/b catenin signaling in melanoma and on the mechanism of action of human anti-CTLA-4 antibody, currently
in phase III clinical trials for the treatment of melanoma.
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INTRODUCTION
Malignant melanoma is a highly aggressive cancer derived
from melanocytes found primarily in the epidermis. With a
dismal 5-year survival rate of 5–15%, the outlook for patients
with metastatic melanoma remains quite bleak (Cummins
et al., 2006), and the incidence of this disease worldwide is
increasing faster than that of any other cancer (Diepgen and
Mahler, 2002). The exact molecular mechanisms underlying
this complex disease remain unresolved, although recent
discoveries have identified some of the crucial cell-signaling
pathways involved in melanoma development and progression,
including the Wnt signaling pathways (Fecher et al., 2007).
Wnts are a family of highly conserved cysteine-rich proteins
that signal through multiple distinct but overlapping pathways.
In the Wnt/b-catenin pathway, the binding of Wnts to Frizzled
receptors and LRP5/6 coreceptors activates a cascade of events
resulting in the accumulation and nuclear translocation of
b-catenin. Nuclear b-catenin interacts with multiple proteins,
including T-cell factor-1/lymphoid enhancing factor-1 (TCF/
LEF) transcription factors, to regulate gene transcription (Logan
and Nusse, 2004; Clevers, 2006). Additionally, several other
Wnts appear to act predominantly through a set of b-catenin-
independent pathways, which are less well defined (Veeman
et al., 2003; Kohn and Moon, 2005). Several studies have
implicated both b-catenin-dependent and b-catenin-indepen-
dent Wnt signaling in melanoma pathogenesis (Weeraratna,
2005; Larue and Delmas, 2006).
Wnt/b-catenin signaling is known to play a critical role
in melanocyte development, raising the question of its role in
melanoma tumorigenesis. A pilot study of Wnt production in
melanoma reported that Wnt-2, Wnt-5, Wnt-7b and Wnt-10b
are synthesized by a subset of melanoma cells (Pham et al.,
2003). b-catenin is increased in several melanoma cell lines
(Rubinfeld et al., 1997), and although mutations in b-catenin
are rare in primary melanomas, nuclear localization of
this protein, an indicator of b-catenin signaling, is frequently
observed (Rimm et al., 1999; Demunter et al., 2002). In
addition, other Wnt pathway components, including adeno-
matous polyposis coli (Worm et al., 2004), inhibitor of
beta-catenin and Tcf-4 (Reifenberger et al., 2002), lymphoid
enhancing factor-1 (LEF1) (Murakami et al., 2001), and
Dickkopf-1 (DKK) (Kuphal et al., 2006) are modified in
melanoma tumors and cell lines. Microphthalmia-associated
transcription factor (MITF) and other known Wnt/b-catenin
target genes, including CCND1, c-MYC, Brn-2, and Nr-CAM,
have also been implicated in melanoma biology (Rodolfo
et al., 2004; Larue and Delmas, 2006; Miller and Mihm, 2006).
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Interestingly, b-catenin-independent Wnt signaling has
been implicated in melanoma progression. Gene array
expression profiling of melanomas identified Wnt-5a as a
robust marker of highly aggressive behavior (Bittner et al.,
2000). Subsequent studies have correlated Wnt-5a and
activation of a b-catenin-independent pathway that involves
protein kinase C with increased cell motility and invasiveness
of UACC 1273 human melanoma cells (Weeraratna et al.,
2002; Dissanayake et al., 2007). In summary, the develop-
ment of malignant melanoma, an aggressive and increasingly
common cancer, is associated with both b-catenin-depen-
dent and b-catenin-independent Wnt signaling, although the
molecular and cellular mechanisms involved are unclear.
To better understand the role of Wnt signaling in
melanoma, we undertook transcriptional profiling of UACC
1273 human melanoma cells following treatment with
recombinant Wnt-3a. We identified cytotoxic T-lymphocyte
antigen-4 (CTLA-4), a potential therapeutic target for mela-
noma (Kasper et al., 2007), as the gene most strongly induced
by Wnt-3a. We then determined that Wnt/b-catenin signaling
directly induces CTLA-4 in human melanoma cells and that
CTLA-4 is expressed in primary melanoma tumors and
melanocytes. These results are relevant to the ongoing
development of human anti-CTLA-4 antibody for the treat-
ment of metastatic melanoma.
RESULTS
Wnt-3a-treated human melanoma cells exhibit transcriptional
changes in known and novel Wnt/b-catenin target genes
To identify genes regulated by the Wnt/b-catenin pathway in
melanoma, we focused on the UACC 1273 human melano-
ma cell line, which has previously been studied in the context
of Wnt-5a signaling (Weeraratna et al., 2002; Dissanayake
et al., 2007). To evaluate the b-catenin-mediated Wnt
responsiveness of these cells, we tested for two hallmarks of
Wnt/b-catenin signaling: (1) activation of a luciferase reporter
vector containing an TCF promoter (TOPFlash); and (2) an
increase in total cellular b-catenin protein following treat-
ment with recombinant Wnt-3a. Wnt-3a increases TOPFlash
activity in a dose-dependent manner and at a concentration
of 500 ngml1 for 6 hours and activates TOPFlash 26-fold
relative to the FOPFlash control reporter, which contains
mutant TCF sites (Figure S1a). Furthermore, after 72 hours
of treatment with 480 ngml1 of recombinant Wnt-3a, the
total amount of b-catenin protein increases relative to
control (Figure S1b, left panel). In support of this result,
6-bromoindirubin-3-oxime, a small molecule activator of
Wnt signaling that works by inhibiting glycogen synthase
kinase 3-beta, also increases b-catenin protein levels
(Figure S1b, right panel). These results suggest that UACC
1273 human melanoma cells can actively signal via the Wnt/
b-catenin pathway by upregulating the levels of b-catenin
and activating TCF-mediated transcription.
Having determined that the cells were responsive to
recombinant Wnt-3a, we next investigated the gene expres-
sion profiles of UACC 1273 cells using the Affymetrix Human
U133 plus 2.0 microarray system, following 6 hours of
treatment with recombinant Wnt-3a. We found that the
expression of 79 genes, 58 upregulated and 21 down-
regulated, was modulated by 1.5-fold or greater in two
independent experiments (Table 1). CTLA-4 increases four-
fold following Wnt-3a stimulation, which is the greatest fold
change observed in our microarray results. Wnt-5a, which
predominantly activates b-catenin-independent Wnt signal-
ing, does not change CTLA-4 levels in similar array studies
using recombinant Wnt-5a (data not shown). Several of the
microarray targets, including c-Jun, LEF1, MITF, BAMBI
(Sekiya et al., 2004), ID2, and CLDN1, are known Wnt/
b-catenin targets genes (http://www.stanford.edu/~rnusse/
pathways/targets.html). In addition to MITF, four upregulated
genes in our array, MC1R, MARCKS, TRPM1, NEDD9, and
two downregulated ones, CLDN1 and CXCL1, have been
implicated in melanoma progression (Manenti et al., 1998;
Dhawan and Richmond, 2002; Chin et al., 2006; Leotlela
et al., 2007). Functional categorization of the entire set of
putative Wnt-3a target genes shows that most of the
overrepresented biological responses are consistent with
previous knowledge about Wnt/b-catenin pathway functions
(Figure S2, Table S1). To verify the microarray results, the
induction/repression of 17 genes was assessed by quantitative
real-time PCR analysis. There is a high degree (77%) of
concordance between the microarray results and these
studies (Table 1, Figure S3). Taken together, these findings
confirm the validity of our microarray screen.
CTLA-4 is expressed in primary melanoma tumor cells and
primary melanocytes
Although CTLA-4 has been detected in melanoma cell lines
(Contardi et al., 2005), its presence in primary melanoma
tumors and melanocytes has not been reported. We
investigated the expression of CTLA-4 in two primary tumors
and human epidermal melanocytes by flow cytometry using
antibodies for CTLA-4 and S100, a marker of melanocytes
and melanoma cells. In all the three samples, the isotype
control antibodies for CTLA-4 and S100 showed low back-
ground staining and were used to set gates (Figures 1a–c).
S100 costaining of the samples with the CTLA-4 isotype
control showed strong expression of S100 in tumors and less
intense staining of melanocytes, confirming the presence of
melanoma and melanocyte cells, respectively (Figures 1d–f).
CTLA-4 is expressed in the strongly S100-positive population
of all the three samples (Figure 1g–i versus d–f see upper right
quadrant). These data are summarized in histograms compar-
ing CTLA-4-isotype control with CTLA-4 staining in the S100-
positive cells (Figures 1j–l). This provides the first report of
CTLA-4 expression from patient melanoma tumor samples.
CTLA-4 transcript and protein levels are elevated by
Wnt/b-catenin signaling
Human CTLA-4 undergoes alternative splicing to yield three
transcripts, including full-length mRNA, a transcript coding
for soluble CTLA-4 that does not contain the transmembrane
region, and a short transcript coding only for the leader
peptide sequence and cytoplasmic tail (Teft et al., 2006). The
full-length and soluble forms may have different functional
effects (Pawlak et al., 2005). Therefore, identification of the
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Table 1. Genes regulated by Wnt-3a in UACC 1273 human melanoma cells by DNA microarray analysis1 and
real-time quantitative PCR analysis2
Fold change3
GeneBank ID Gene title Gene symbol Experiment 1 Experiment 2
NM_005214** Cytotoxic T-lymphocyte-associated protein 4 CTLA4 4.29 4.00
AB046817** Synaptotagmin-like 2 SYTL2 4.29 4.00
BF196943*** Ubiquitin-specific peptidase 53 USP53 3.03 2.64
NM_016235 G protein-coupled receptor, family C, group 5, member B GPRC5B 2.83 2.64
BG034972 Melanocortin 1 receptor MC1R 2.83 2.83
AI967987 Melanoma-associated antigen (mutated) 1-like 1 MUM1L1 2.83 2.64
D14826*** cAMP-responsive element modulator CREM 2.64 2.64
AB007941** Receptor-interacting protein kinase 5 RIPK5 2.64 1.74
BE881590** ets variant gene 1 ETV1 2.64 1.62
AU151107 CDNA FLJ12909 fis, clone NT2RP2004400 — 2.64 1.87
AW163148*** Myristoylated alanine-rich protein kinase C substrate MARCKS 2.46 1.74
NM_014705 Dedicator of cytokinesis 4 DOCK4 2.46 2.00
NM_002852 Pentraxin-related gene, rapidly induced by IL-1 b PTX3 2.46 2.64
R61374** Hairy/enhancer-of-split related with YRPW motif 1 HEY1 2.46 2.14
NM_006379 Semaphorin 3C SEMA3C 2.30 1.74
AY014180** SMAD-specific E3 ubiquitin protein ligase 2 SMURF2 2.30 2.00
AI754416*** CDC42 effector protein (Rho GTPase binding) 3 CDC42EP3 2.30 2.14
BF978541*** Protein kinase D3 PRKD3 2.30 2.46
AI277662** Transient receptor potential cation channel, M, member 1 TRPM1 2.30 1.74
AI949392 Semaphorin 4C SEMA4C 2.30 1.62
AI857639 Phorbol-12-myristate-13-acetate-induced protein 1 PMAIP1 2.14 1.62
AW006123** F-box protein 32 FBXO32 2.14 2.14
AI744591 Chromosome 21 open reading frame 63 C21orf63 2.14 2.83
NM_005195 CCAAT/enhancer binding protein (C/EBP), delta CEBPD 2.00 2.14
NM_002514** Nephroblastoma-overexpressed gene NOV 2.00 2.30
NM_016629 Tumor necrosis factor receptor superfamily, member 21 TNFRSF21 2.00 2.30
BF432648 Tumor necrosis factor receptor superfamily, member 19 TNFRSF19 2.00 1.74
AI870144*** Pleckstrin homology, Sec7 and coiled-coil domains 3 PSCD3 2.00 2.00
BG491844 v-jun sarcoma virus 17 oncogene homolog JUN 1.87 1.87
NM_000222 v-kit Hardy–Zuckerman 4 feline sarcoma viral oncogene homolog KIT 1.87 1.87
AA541479 Mitogen-activated protein kinase 1 MAP3K1 1.87 1.62
AW043602 KIAA1946 KIAA1946 1.87 1.62
BE302305** Transducin-like enhancer of split 1 TLE1 1.87 1.62
W22625** PR domain containing 4 PRDM4 1.87 2.00
NM_004417 Dual specificity phosphatase 1 DUSP1 1.74 1.87
AI738896 Tumor necrosis factor, a-induced protein 3 TNFAIP3 1.74 1.62
NM_004226 Serine/threonine kinase 17b (apoptosis-inducing) STK17B 1.74 1.74
NM_000024 Adrenergic, b-2-receptor, surface ADRB2 1.74 1.87
NM_001321 Cysteine and glycine-rich protein 2 CSRP2 1.74 1.74
AF294627** Lymphoid enhancer-binding factor 1 LEF1 1.74 1.74
AF255647 Transmembrane protein 163 TMEM163 1.74 1.41
NM_001554 Cysteine-rich, angiogenic inducer, 61 CYR61 1.62 1.52
U64317 Neural precursor cell expressed, developmentally downregulated 9 NEDD9 1.62 1.52
NM_003165 Syntaxin-binding protein 1 STXBP1 1.62 1.62
N25732** Forkhead box O3A FOXO3A 1.62 1.52
NM_004694** Solute carrier family 16, member 6 SLC16A6 1.62 2.00
BF674052 MicroRNA 21 MIRN21 1.62 1.74
NM_012342 BMP and activin membrane-bound inhibitor homolog BAMBI 1.52 1.62
NM_001995 Acyl-CoA synthetase long-chain family member 1 ACSL1 1.52 1.41
Table 1 continued on the following page
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form of CTLA-4 induced by Wnt-3a may help to elucidate its
function in melanoma. To this end, the mRNA transcripts
were analyzed in UACC 1273 cells as well as the commonly
studied A2058 human melanoma cell line by reverse
transcriptase-PCR (RT-PCR) amplification using primers that
flank the ATG initiation and translation termination codons.
Only full-length CTLA-4 was detected in UACC1273 and
A2058 cell lines following 6 hours of recombinant Wnt-3a
stimulation (Figure 2a). To validate CTLA-4 induction by
Wnt-3a in melanoma, we measured CTLA-4 transcript by
real-time quantitative RT-PCR using two distinct sets of
primers. Using primers that detect any isoform of CTLA-4, we
found that CTLA-4 is elevated 5.9-fold and 4.4-fold in UACC
1273 and A2058 cells, respectively, following Wnt-3a
treatment (Figure 2b). To confirm that the full-length form
of CTLA-4 is induced by Wnt-3a specifically through Wnt/b-
catenin signaling, primers specific for this splice variant were
used to analyze CTLA-4 transcript by real-time RT-PCR in
both cell lines following 6 hours treatment with Wnt-3a-
conditioned media in the presence or absence of DKK-1, a
secreted protein that inhibits the Wnt/b-catenin pathway by
direct binding to the LRP5/6 Wnt coreceptor. DKK-1 blocks
Wnt-3a induction of full-length CTLA-4 message in both cell
lines (Figure 2c).
Next, we evaluated CTLA-4 protein expression in UACC
1273 cells by flow cytometry following treatment with Wnt-
3a conditioned media for 72 hours. In fixed and permeabi-
lized cells, levels of total CTLA-4 increased in Wnt-3a relative
Table 1. Continued
Fold change3
GeneBank ID Gene title Gene symbol Experiment 1 Experiment 2
BG054916 Patched homolog 1 (Drosophila) PTCH1 1.52 1.52
AF015043 SH3-domain-binding protein 4 SH3BP4 1.52 1.62
AW021102 Hypothetical LOC401328 — 1.52 1.87
BE967118 Transducin-like enhancer of split 3 TLE3 1.52 1.52
AI880633 Coiled-coil domain containing 75 CCDC75 1.52 1.52
W87901 Small nuclear ribonucleoprotein polypeptide E — 1.41 2.00
BG537255 DNAJ (Hsp40) homolog, subfamily B, member 1 DNAJB1 1.32 1.52
NM_000248 Microphthalmia-associated transcription factor MITF 1.32 1.52
N20927 RAP2B, member of RAS oncogene family RAP2B 1.23 1.62
BC002670 SERTA domain containing 1 SERTAD1 1.41 1.52
D13891 Inhibitor of DNA binding 2///inhibitor of DNA binding 2B ID2///ID2B 1.62 1.87
NM_014575 Schwannomin-interacting protein 1 SCHIP1 1.62 1.74
NM_004430 Early growth response 3 EGR3 1.62 1.87
NM_000475 Nuclear receptor subfamily 0, group B, member 1 NR0B1 1.62 1.41
M57731 Chemokine (C-X-C motif) ligand 2 CXCL2 1.62 2.00
N71923 Fibronectin leucine-rich transmembrane protein 3 FLRT3 1.62 1.87
AI474448 Zinc finger protein 689 ZNF689 1.62 1.32
NM_000362 TIMP metallopeptidase inhibitor 3 TIMP3 1.74 1.74
NM_019058 DNA-damage-inducible transcript 4 DDIT4 1.74 2.14
NM_021106 Regulator of G-protein signaling 3 RGS3 1.74 1.52
NM_000376 Vitamin D3 (1,25-dihydroxyvitamin) receptor VDR 1.74 1.74
NM_003236 Transforming growth factor, a TGFA 1.74 2.00
AV725664 Phosphatidic acid phosphatase type 2B PPAP2B 1.74 2.00
AL049369 Down syndrome critical region gene 1 DSCR1 1.74 1.32
AF284225 Doublesex and mab-3-related transcription factor 2 DMRT2 1.74 1.74
AF101051 Claudin 1 CLDN1 1.87 1.41
BC006428** CXXC finger 5 /// CXXC finger 5 CXXC5 1.87 1.74
NM_001511 Chemokine (C-X-C motif) ligand 1 CXCL1 2.00 2.00
BF528433 Hairless homolog (mouse) HR 2.00 1.74
D13889 Inhibitor of DNA binding 1 ID1 2.14 2.30
1UACC 1273 cells were treated with 480 ngml1 recombinant Wnt-3a or vehicle (BSA) for 6 hours and were subject to Affymetrix-based expression profiling
using the Human Genome U133 Plus 2.0 arrays.
2Genes validated by real-time RT-PCR are highlighted.
3Fold change is calculated relative to BSA and is listed for each of two independent experiments. Only genes that changed similarly in both experiments and
that changed 1.5-fold or greater are listed.
*Refers to the number of hits for the gene.
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to control-conditioned media-treated cells (Figure 3a); how-
ever, surface expression, in live nonpermeabilized cells,
remained unchanged (Figure 3b). There was no change in
surface expression levels at 4, 12, 24, and 48 hours (data not
shown). We also observed that low but detectable levels of
CTLA-4 were expressed in both control-treated and untreated
cells (data not shown), suggesting that UACC 1273 cells
constitutively express CTLA-4. Expression was also observed
in untreated A2058 and Mel 375 melanoma cell lines (data
not shown). In summary, our results demonstrate that Wnt/b-
catenin signaling induces the expression of CTLA-4 in human
melanoma cells at both the transcript and protein levels.
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Figure 1. CTLA-4 is expressed in human epidermal melanocytes and primary melanoma tumors. Dissociated human epidermal melanocytes (HEM) and
two primary melanoma tumors (Mel 1, Mel 2), were analyzed for CTLA-4 (PE) and S100 (Alexa Fluor 633) expression by flow cytometry. (a) HEM, (b) Mel 1,
and (c) Mel 2 were costained with the isotype control antibodies for both S100 and CTLA-4. Gates for S100- and CTLA-4-negative cell populations were
set based on these results. (d) HEM, (e) Mel 1, and (f) Mel 2 were costained with S100 antibody and the isotype control antibody for CTLA-4. (g) HEM, (h) Mel 1,
and (i) Mel 2 were costained with S100 antibody and CTLA-4 antibody. Blue, strongly S100-positive cells only. Red, CTLA-4-positive and strongly S100-positive
cells. (j–l) Histograms of CTLA-4 expression in S100 positive cells comparing CTLA4-isotype control antibody (black) with anti-CTLA-4 antibody (red) in
(j) HEM, (k) Mel 1, and (l) Mel 2. Quadrant values represent percent of gated cells stained.
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The CTLA-4 promoter is directly regulated through a single
TCF/LEF consensus site
We next investigated whether CTLA-4 is regulated by the
Wnt/b-catenin pathway directly or indirectly. Inspection of
the 1704bp region immediately 50 of the transcriptional
start site of CTLA-4 revealed the presence of four potential
TCF/LEF transcriptional response elements (Figure 4a). To test
whether these sites are important for the regulation of CTLA-4
expression, we isolated this region by PCR and subcloned it
upstream of a luciferase reporter (WT). In A2058 cells, Wnt-
3a increased CTLA-4 promoter activity relative to the control
in a dose-dependent manner, up to 4.5-fold (Figure 4b).
Wnt-3a activation of this promoter was blocked by DKK-1-
conditioned media, a known inhibitor of Wnt signaling
(Figure 4b). These results support the hypothesis that CTLA-4
is transcriptionally regulated by the Wnt/b-catenin pathway.
To test whether any of the four potential TCF/LEF binding
sites are required for the observed Wnt-3a-responsiveness of
the WT reporter, we introduced site-specific mutations into
each of these sites by PCR (Figure 4a) and constructed a set of
luciferase reporter vectors, each containing one mutant site.
The ability of Wnt-3a to increase CTLA-4 promoter-driven
luciferase expression was attenuated by an A-to-G mutation
at position 116 in the second TCF-binding element
(at 114 to 119) within the CTLA-4 promoter (Mut 2),
strongly suggesting that the induction of CTLA-4 transcription
by Wnt signaling is dependent upon the activity of TCF/LEF
transcription factors (Figure 4c).
DISCUSSION
Although it is clear that activation of Wnt/b-catenin signaling
can be important in melanoma progression, the molecular
details remain unclear. In this study, we investigated the
transcription profile of human melanoma cells following
Wnt-3a treatment and identified CTLA-4 as a direct transcrip-
tional target of the Wnt/b-catenin signaling pathway.
Furthermore, we made the initial observation that CTLA-4 is
expressed in patient-derived melanoma tumors. Given the
pivotal role of CTLA-4 in inhibiting immune responses, these
results may offer insight into the regulation of CTLA-4 in
several autoimmune diseases and malignancies.
The predominant role of CTLA-4 as a negative regulator of
T cell-mediated immune responses has led to widespread
interest in making it a target of mAb therapy to boost
antitumor immunity. CTLA-4 blockade leads to enhancement
of immune response (Leach et al., 1996), rejection of tumors
(Hurwitz et al., 2000), or reduction of tumors in mice when
used in combination with tumor vaccines (van Elsas et al.,
1999). Promising preclinical results have led to the develop-
ment of fully humanized anti-CTLA-4 antibodies that are
currently being tested in over 10 clinical trials, including a
phase III trial for the treatment of metastatic melanoma
(Kasper et al., 2007). Although recent studies have reported
the expression of CTLA-4 (Contardi et al., 2005) and its ligand
B7.1 (CD80) in melanoma cell lines (Tirapu et al., 2006), as
well as linked CTLA-4 gene polymorphisms with malignancy
susceptibility (Zheng et al., 2001; Ghaderi et al., 2004;
Monne et al., 2004), the function of CTLA-4 in melanoma is
unknown.
We observed that Wnt/b-catenin signaling induces the
expression of CTLA-4 in human melanoma cells at both the
transcript and protein levels. In both UACC 1273 and A2058
750
500
250
EV CT
LA
-4
UA
CC
12
73
ev
A2
05
8
fl CTLA-4
8.0
7.0
6.0
5.0
4.0
3.0
2.0
0.0
1.0
8.0
7.0
6.0
5.0
4.0
3.0
2.0
0.0
1.0
BSA r3a
UACC1273ev
A2058
UACC1273ev
A2058
Fo
ld
 c
ha
ng
e
Fo
ld
 c
ha
ng
e
Control Wnt-3a
Wnt-3a
GFP DKK-1
Figure 2. CTLA-4 transcript is induced by Wnt/b-catenin signaling in
two melanoma cell lines. (a) RT-PCR analysis of CTLA-4 transcript splice
variants in A2058 melanoma cells transiently transfected with empty vector
(EV) or full-length CTLA-4 (CTLA-4) and UACC 1273 and A2058 cells treated
with recombinant Wnt-3a for 6 hours. (b) Real-time quantitative PCR analysis
of CTLA-4 expression in UACC 1273 and A2058 cells treated with
recombinant Wnt-3a or vehicle (BSA) for 6 hours. (c) Real-time quantitative
PCR analysis of CTLA-4 expression in UACC 1273 and A2058 cells treated
for 6 hours with Wnt-3a-conditioned media (Wnt-3a) or vehicle (control)
alone or in the presence of DKK-1 conditioned media or vehicle (green
fluorescent protein). Expression of CTLA-4 was normalized by comparison
to GAPDH and 18S (not shown) as internal controls. Fold change is
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Figure 3. Wnt-3a increases total CTLA-4 protein levels in UACC 1273
melanoma cells. UACC 1273 cells treated with Wnt-3a-conditioned media or
vehicle for 72 hours were stained with isotype control or CTLA-4 antibodies
and analyzed by flow cytometry. (a) Histogram of total cellular CTLA-4
expression in fixed, permeabilized cells. (b) Histogram of surface CTLA-4
expression of live, nonpermeabilized cells. Plot is depicted as % cells of
maximum versus fluorescence intensity. Dotted black, isotype control
antibody for both treatment conditions; blue, vehicle, CTLA-4 antibody;
red, Wnt-3a-conditioned media, CTLA-4 antibody. Data represent one
of four identical experiments.
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melanoma cell lines, the full-length splice variant of CTLA-4
is elevated by Wnt-3a. This induction is specifically mediated
by b-catenin, as it is attenuated by the Wnt/b-catenin
pathway inhibitor, DKK-1. The observed increase in
CTLA-4 message is accompanied by an increase in total
protein levels, although without concomitant changes in cell
surface expression.
There may be a few plausible explanations for the
discrepancy between low or undetectable surface expression
and functional effects. In T cells, CTLA-4 is tightly regulated
by restricted trafficking to the cell surface (Iida et al., 2000)
and rapid internalization (Chuang et al., 1997). Even during
maximal expression of CTLA-4 after T-cell activation, surface
CTLA-4 constitutes less than 10% of the total cellular protein,
and little can be detected (Alegre et al., 1996; Alegre et al.,
1998; Anna et al., 2003). Strikingly, several studies have
reported functional effects in T cells even when surface levels
of CTLA-4 are undetectable (Krummel and Allison, 1996;
Walunas et al., 1996; Fallarino et al., 2003). Similarly, in
melanoma cell lines, studies have shown that although
low levels of intracellular but not cell surface CTLA-4 are
detectable, apoptosis could be induced following treat-
ment with CTLA-4 ligands, B7.1 (CD80) and B7.2 (CD86),
suggesting the presence of functional receptor on the surface
(Contardi et al., 2005). An alternative possible explanation is
that Wnt-mediated induction of CTLA-4 expression in
melanoma cells is solely intracellular and has a yet unknown
function. These published studies suggest that although we do
not detect a change in CTLA-4 cell surface expression, this
does not preclude the increase in total expression from
having physiological consequences.
Finally, we analyzed a 1.7 kb region of the CTLA-4
promoter containing four putative TCF/LEF binding sites to
address whether CTLA-4 is directly or indirectly regulated by
the Wnt/b-catenin pathway. We found that Wnt-3a increases
CTLA-4 promoter activity through a single TCF/LEF binding
site located at 114 to 119 from the transcriptional start
site. This result is supported by the finding that LEF1 increases
CTLA-4 transcription from a polymorphic promoter variant at
position 318bp, which is located within a TCF/LEF
consensus site (Anjos et al., 2004; Chistiakov et al., 2006).
This required TCF/LEF site lies within the 335-bp region of the
CTLA4 promoter, shown to be essential for the induction of
the CTLA4 expression (Perkins et al., 1996), suggesting the
importance of Wnt/b-catenin signaling in regulating CTLA-4
expression.
The potential function of CTLA-4 in the activity of regu-
latory T cells (Treg), a subpopulation of T cells involved in
suppressing host immune responses to prevent autoimmune
diseases, and alternatively to promote tumor immunity
(Wang and Wang, 2007), may offer a possible explanation
for the role of Wnt/b-catenin pathway-mediated CTLA-4
induction in melanoma cells. Several studies have suggested
that ligation of B7 molecules expressed on dendritic cells
with recombinant soluble forms of CTLA-4 or CTLA-4 expres-
sed on Tregs induces tryptophan catabolism by increasing the
expression of indoleamine 2,3-dioxygenase in dendritic cells
(Mandelbrot et al., 2001; Grohmann et al., 2002; Fallarino
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Figure 4. CTLA-4 promoter is directly regulated by Wnt/b-catenin pathway
through a single TCF/LEF transcription factor consensus site. (a) Schematic
representation of CTLA-4 promoter. TCE/LEF consensus sites are numbered
1–4 with location from transcriptional start site and nucleotide sequence listed
above and below, respectively. Mutated sequence is italicized. (b) A2058
cells transiently transfected with a luciferase reporter construct (WT)
containing 1.7 kb (upstream of the transcriptional start site) of the CTLA-4
promoter were treated with two doses of Wnt-3a conditioned media or
vehicle (control) alone or in the presence of DKK-1-conditioned media or
vehicle (green fluorescent protein). (c) A2058 cells transfected with the WT
reporter and mutant reporters, each containing a single mutated TCF/LEF
consensus site (Mut 1–4), were treated with Wnt-3a-conditioned media or
vehicle (control). CTLA-4 promoter reporter activity was normalized by
cotransfection with a renilla luciferase reporter. Changes in normalized
luciferase activity are represented as fold change relative to untreated
reporter. Data represent three independent experiments. Error bars indicate
standard deviation. Asterisk denotes statistically significant change
(Po0.05) by unpaired two-tailed Student’s t-test.
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et al., 2003). This results in T cell suppression by depleting
the essential amino acid and inhibiting growth or by inducing
apoptosis from tryptophan metabolites. In support of this
idea, CTLA-4 expressed on activated CD4þ T cells can
stimulate indoleamine 2,3-dioxygenase in dendritic cells
(Munn et al., 2004). Thus, it is interesting to speculate that
ligation of CTLA-4, induced by Wnt/b-catenin signaling,
in melanoma cells with B7 molecules on dendritic cells in
the tumor microenvironment may shield target tumor cells
against T-cell-mediated destruction by inducing tryptophan
catabolism.
The regulation of CTLA-4 by Wnt/b-catenin signaling and
expression of CTLA-4 in melanoma tumors is likely relevant
to ongoing clinical trials of CTLA-4 antibody therapy in
patients with metastatic melanoma. Although CTLA-4 block-
ade has been shown to increase autoimmunity and antitumor
immunity, the mechanisms underlying these effects remain
controversial. As a high level of CTLA-4 is constitutively
expressed on Tregs (Takahashi et al., 2000), the effects of
CTLA-4 blockade have been attributed to Treg depletion,
which may elicit an autoimmune response that leads to an
antitumor effect (Attia et al., 2005). A second hypothesis,
however, posits that CTLA-4 blockade may not work through
Treg depletion, but rather by preventing the inhibitory signals
usually triggered by B7-CTLA-4 engagement, with a net
consequence of increased activation (Maker et al., 2005).
Furthermore, several studies suggest that activation of CTLA-4
in cultured tumor cells has some inhibitory role, as
engagement of CTLA-4 by soluble ligand results in apoptosis
(Pistillo et al., 2003; Contardi et al., 2005; Laurent et al.,
2007). Based on our findings, further studies are needed to
address how differences in tumor CTLA-4 levels may relate to
differences in patient responses to CTLA-4 blockade. If,
indeed, CTLA-4 expression on tumors can affect patient
responses to anti-CTLA-4 therapy, then modulation of Wnt/
b-catenin signaling by small molecules may provide a
potential therapeutic avenue.
MATERIALS AND METHODS
Approval of all described studies by the University of Washington
was not necessary.
Cell lines and primary melanoma tumors
UACC 1273 cells were a gift from Dr Ashani T. Weeraratna
(National Institute on Aging, Baltimore, MD). Primary melanoma
tumors and A2058 human melanoma cells were gifts from
Dr Cassian Yee (Fred Hutchinson Cancer Center, Seattle, WA).
The tumors were obtained from patients in accordance with IRB
guidelines. Mouse L cells or L cells that stably express Wnt3a were
a gift from Dr Roel Nusse (Stanford University, Stanford, CA).
Recombinant Wnt and conditioned media
Recombinant Wnt-3a was a generous gift from Dr Steven J. Staats
and Dr Irwin D. Bernstein (both from Fred Hutchinson Cancer
Center, Seattle, WA). Wnt3a and control-conditioned media were
prepared as described (Willert et al., 2003). Preparation of Dkk-1 or
green fluorescent protein (control) containing conditioned media is
fully detailed in the Supplementary Methods.
Constructs
Full-length CTLA-4 expression construct was created with standard
PCR-based cloning strategies. A 1.7 kb region of the CTLA-4
promoter, upstream of the transcriptional start site, was cloned into
pGL3 Basic (Promega, Madison, WI) with standard PCR-based
cloning strategies. Mutations were made in the TCF/LEF consensus
sites of this promoter using site-directed PCR-based mutagenesis
followed by cloning into pGL3 Basic. All oligos used are detailed in
the supplement (Table S2).
Preparation of cell extracts and western blot analysis
UACC 1273 cells seeded into a 6-well plate were treated with
480ngml1 BSA, 480ngml1 recombinant Wnt-3a, DMSO, or 1uM
6-bromoindirubin-3-oxime (Calbiochem, San Diego, CA) for 72hours.
Total cell lysates were analyzed by western blotting with polyclonal
anti-b-catenin (9562; Cell Signaling, Danvers, MA) at 1:5,000, and/or
monoclonal anti-b-tubulin antibodies (T7816; Sigma, St Louis, MO) at
1:10,000 as described previously (Angers et al., 2006). Western blots
were repeated twice.
RNA isolation, reverse transcription, and quantitative
real-time PCR
Total RNA was extracted using the RNeasy kit (Qiagen, Valencia,
CA) according to the manufacturer’s protocol for all treatment
conditions as detailed in the Supplementary Methods. Single-
stranded cDNA synthesis and quantitative real-time PCR analysis
were performed as described previously (Major et al., 2007). The
oligos used for target genes and for the internal controls, GAPDH
and 18S, are detailed in the supplement (Table S2). Real-time PCR
experiments were conducted in duplicate and repeated 3–5 times.
Transient transfections and luciferase reporter assays
All transient transfections were performed using Lipofectamine 2000
(Invitrogen, Lakewood, NJ) according to the manufacturer’s recom-
mendations. Stable expression of SuperTOPFlash reporter (Kaykas et al.,
2004) or TCF/LEF mutated fuBAR reporter (Major et al., 2007) and
renilla luciferase reporter (Promega) in UACC 1273 cells was achieved
by lentiviral-mediated transduction. TOPFlash, CTLA-4 promoter, and
CTLA-4 promoter mutants luciferase assays were performed in
accordance with the dual luciferase assay specifications (Promega)
using the Mithras LB940 luminometer (Berthold, Bad Wildbad,
Germany) and are detailed in the Supplementary Methods. Reporter
assays were conducted in duplicate and repeated 3–5 times.
Affymetrix microarray analysis
Total RNA extracted from UACC 1273 cells seeded into a 6-well
plate and treated with 480 ngml1 BSA or 480 ngml1 recombinant
Wnt-3a for 6 hours was subject to RNA quality control, target
labeling, hybridization to Affymetrix Human Genome U133 Plus 2.0
chips (Affymetrix, Santa Clara, CA), and scanning by the Center
for Array Technology (University of Washington, Seattle, WA,
http://ra.microslu.washington.edu/). Data were analyzed using
GCOS (GeneChip Operating System, Affymetrix, Santa Clara, CA)
software as described in the Supplementary Methods.
Flow cytometry for CTLA-4 expression
Wnt-3a or control-conditioned media-treated UACC 1273 cells,
human epidermal melanocytes, and dissociated primary melanoma
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tumor were stained with appropriate antibody (PE-CTLA-4, BD
Pharmingen, San Jose, CA, no. 555853; Control for CTLA-4, BD
Pharmingen, no. S100; Dako, Carpentaria, CA, no. Z3011; Control for
S100, Dako, no. X0936; Alexa Fluor 633, Invitrogen, no. A21070) and
analyzed using either BD FACScan flow cytometer (BD Biosciences,
San Jose, CA) and Cell Quest software for UACC 1273 cells or Influx
flow cytometer (Cytopeia Inc., Seattle, WA) and FCSExpress (Denovo
software, Los Angeles, CA) for melanocytes and tumors as detailed in
the Supplementary Methods. Antibodies and antibody combinations
were extensively tested at several concentrations (data not shown).
CTLA-4 expression studies in UACC 1273 cells and melanocytes/
tumors were repeated thrice and twice, respectively.
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